Diseases [C] » Cardiovascular Diseases [C14] » Heart Diseases » Cardiomyopathies
Description
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). MeSH
Hierarchy View
Subtype Terms (14)
Arrhythmogenic Right Ventricular Dysplasia
2 approved drugs
Cardiomyopathy, Alcoholic
1 approved drug
Cardiomyopathy, Dilated
49 drugs (27 approved, 22 experimental)
Cardiomyopathy, Hypertrophic
30 drugs (20 approved, 10 experimental)
Chagas Cardiomyopathy
9 drugs (8 approved, 1 experimental)
Diabetic Cardiomyopathies
5 drugs (2 approved, 3 experimental)
Endocardial Fibroelastosis
3 drugs (2 approved, 1 experimental)
Endomyocardial Fibrosis
12 drugs (10 approved, 2 experimental)
Glycogen Storage Disease Type IIb
1 experimental drug
Myocardial Reperfusion Injury
23 drugs (18 approved, 5 experimental)
Myocarditis
9 approved drugs
Phase 4 Indicated Drugs (26)
Phase 3 Indicated Drugs (17)
Phase 1 Indicated Drugs (8)
Other Experimental Indicated Drugs (20)
Organization Involved with Phase 4 Indications (74)
Autonomous University of Madrid
Cardiovascular Imaging Technologies
Chinese Academy of Medical Sciences
Clinica Universidad de Navarra
Huazhong University of Science and Technology
Midwest Cardiovascular Research Foundation
National Heart, Lung, and Blood Institute (NHLBI)
Shahid Beheshti University of Medical Sciences
Silesian University of Medicine
The Physicians' Services Incorporated Foundation
The University of Texas, Dallas
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
University of California, San Francisco
Organization Involved with Phase 3 Indications (60)
Andalusian Initiative for Advanced Therapies
Andalusian Initiative in Advanced Therapies
Aristotle University of Thessaloniki
Assistance Publique - Hôpitaux de Paris
Canadian Cardiovascular Society
Fundação de Amparo à Pesquisa do Estado de São Paulo
Fundación Cardioinfantil Instituto de Cardiología
Fundación Cardiovascular de Colombia
Heart and Stroke Foundation of Canada
Hospital Regional Universitario Carlos Haya
Hospital Universitario Puerta del Mar
Institute for Cardiovascular Diseases of Vojvodina
Institut National de la Santé Et de la Recherche Médicale, France
National Natural Science Foundation of China
Organization Involved with Phase 2 Indications (95)
Advanced Accelerator Applications
Amphia Hospital Breda, the Netherlands
Bambino Gesù Hospital and Research Institute
Blood Transfusion Centre of Slovenia
Cardiovascular Cell Therapy Research Network
Case Western Reserve University
Fundacion Investigacion y Desarrollo
General Hospital of Armed Police, Beijing
German Federal Ministry of Education and Research
Gottfried Wilhelm Leibniz Universität Hannover
Icahn School of Medicine at Mount Sinai
International Heart Institute of Montana
Iran University of Medical Sciences
Ivy Institute of Stem Cells Co. Ltd
Medical City Children's Hospital, Dallas
National Cancer Institute (NCI)
National Center for Research Resources (NCRR)
New England Research Institutes
Oregon Health and Science University
Russian Academy of Medical Sciences
South China Research Center for Stem Cell and Regenerative Medicine
Tennessee Center for Clinical Trials
The Foundation Institute San Raffaele G. Giglio of Cefalù
The Research-Clinical Center for Cardiac Surgery and Transplantology LLP
Organization Involved with Phase 1 Indications (19)
Organization Involved with Other Experimental Indications (23)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
